On January 16, the US Food and Drug Administration (FDA) granted traditional approval to acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.

For more information read the FDA announcement and the AstraZeneca press release.

Posted on 1/17/2025